SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549
                               ------------------

                                    FORM 6-K

                        REPORT OF FOREIGN PRIVATE ISSUER

                    Pursuant to Rule 13a-16 or 15d-16 of the
                         Securities Exchange Act of 1934


                           For the month of: July 2003

                        Commission File Number: 000-28882

                             World Heart Corporation
               --------------------------------------------------
               (Exact name of registrant as specified in charter)

                                       N/A
                 -----------------------------------------------
                 (Translation of registrant's name into English)

                                     Ontario
                          -----------------------------
                         (Jurisdiction of organization)


                     1 Laser Street, Ottawa, Ontario K2E 7V1
                    ----------------------------------------
                    (Address of principal executive offices)

                  Registrant's telephone number: (613) 226-4278



Indicate by check mark whether the registrant  files or will file annual reports
under cover of Form 20-F or Form 40-F.

                              Form 20-F X      Form 40-F
                                       ---

Indicate by check mark whether by furnishing the  information  contained in this
Form,  the  registrant  is  also  thereby  furnishing  the  information  to  the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

                                   Yes         No X
                                       ---       ---

If "Yes" is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b): 82- ________


<PAGE>


This Form 6-K consists of the following:

1.   Press release of World Heart Corporation (the "WorldHeart")  dated July 10,
     2003  announcing  that Lehman  Brothers  has revised and reissued a July 8,
     2003  Company  Update for Thoratec  Corporation  that  contained  incorrect
     information regarding WorldHeart's Novacor(R) LVAS (left ventricular assist
     system) product.

<PAGE>


News Release

For Immediate Release


                LEHMAN BROTHERS ISSUES CORRECTION TO JULY 8, 2003
     COMPANY UPDATE: Unfounded Reference to World Heart Corporation Removed


OTTAWA  - July  10,  2003  (OTCBB:WHRTF,  TSX:  WHT) - World  Heart  Corporation
(WorldHeart) today announced that, at WorldHeart's request,  Lehman Brothers has
revised and reissued a July 8, 2003 Company Update for Thoratec Corporation. The
July 8 update  contained  incorrect and unfounded  suggestions  that  WorldHeart
would need additional  studies to obtain approval for use of its Novacor(R) LVAS
(left  ventricular  assist  system) by patients who are not candidates for heart
transplantation.

"As we have announced,  we are in active  discussion with the U.S. Food and Drug
Administration (FDA) to seek an expanded indication for Novacor LVAS. We expect,
but cannot be certain  that, a positive  decision  will result from this process
during this year," Rod Bryden, WorldHeart's President and CEO, said.

"We  felt  it  necessary  to  offer  clarification   because  the  comments  and
impressions left by that report affected  WorldHeart and its  shareholders," Mr.
Bryden added.

Novacor LVAS is an  electromagnetically  driven pump that  provides  circulatory
support by taking over part or all of the workload of the left ventricle.  It is
commercially  approved as a bridge to transplantation in the U.S. and Canada. On
November  22,  2002,  the  FDA  filed  WorldHeart's   Premarket  Approval  (PMA)
Supplement seeking destination-therapy indication for its Novacor LVAS.

In Europe, the Novacor LVAS device has unrestricted approval for use as a bridge
to  transplantation,  an alternative to transplantation  and to support patients
who may have an ability to recover the use of their natural heart. In Japan, the
device is currently commercially approved for use in cardiac patients at risk of
imminent death from  non-reversible  left ventricular failure for which there is
no alternative except heart transplantation.


World  Heart  Corporation,  a global  medical  device  company  based in Ottawa,
Ontario and Oakland,  California,  is currently  focused on the  development and
commercialization  of pulsatile  ventricular assist devices. Its Novacor(R) LVAS
(Left Ventricular  Assist System) is well established in the marketplace and its
next-generation  technology,  HeartSaverVAD(TM),  is a fully implantable  assist
device intended for long-term support of patients with end-stage heart failure.

                                                               .../2

<PAGE>

Any  forward-looking  statements  in this release are made  pursuant to the safe
harbour  provisions  of the Private  Securities  Litigation  Reform Act of 1995.
Investors are cautioned  that all  forward-looking  statements  involve risk and
uncertainties,  including without  limitation,  risks in product development and
market  acceptance  of and  demand  for the  Corporation's  products,  risks  of
downturns in economic conditions generally,  and in the medical devices markets,
risks  associated  with  costs  and  delays  posed  by  government   regulation,
limitations  on third  party  reimbursement,  inability  to protect  proprietary
technology,  potential  product  liability  and  other  risks  detailed  in  the
Corporation's  filings with the U.S.  Securities  and Exchange  Commission.  All
financial  figures are prepared in accordance with Canadian  generally  accepted
accounting principles (GAAP) and are expressed in Canadian dollars.


For more information, please contact:

Michelle Banning
Manager, Corporate Communications
(613) 226-4278, ext: 2995 or (510) 563-4995
communications@worldheart.com


<PAGE>

                                   SIGNATURES

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned, thereunto duly authorized.


                                         World Heart Corporation


     Date: July 10, 2003                 By:  /s/  Ian Malone
                                            ------------------------------------
                                            Name:   Ian Malone
                                            Title:  Vice President Finance and
                                                    Chief Financial Officer